Year: 2021
Type: editorial
Abstract: in hospitalized patients, including in those requiring supplemental oxygen, but not in those requiring ICU level care, may reflect better management of patients over time, but also highlight the significance of early introduction of various anti-COVID-19 therapies to prevent clinical deterioration to ICU level care.The findings that corticosteroids increased both secondary infections and death rates in patients with CLL and COVID-19 are intriguing.In the RECOV-ERY trial, 8 the use of dexamethasone improved survival in patients hospitalized with COVID-19 who received respiratory support.Perhaps the impaired immune reactions in patients with CLL moderate the hyperinflammatory reactions to COVID-19, thus turning corticosteroids beneficial effects to somewhat redundant in this frail population.
Source: Blood
Author: Rachel E. Rau
Institution: Texas Children's Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W3208401101